Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
April 20 2017 - 10:05AM
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical
company creating novel epigenetic therapies, today announced that
the Company will release its first quarter 2017 financial results
on Monday, May 8, 2017.
Epizyme also announced that two posters on interim efficacy and
safety data from its ongoing Phase 2 study of tazemetostat in adult
patients with molecularly defined solid tumor will be presented on
June 6, 2017 at the American Society of Clinical Oncology (ASCO)
Annual Meeting in Chicago. The Company plans to hold a conference
call to discuss the interim findings on Thursday, May 18, 2017 at
8:30 a.m. ET, after the ASCO abstracts have been released.
Considering the planned conference call, Epizyme will not host a
separate conference call to discuss its first quarter 2017
financial results.
The Phase 2 data posters will be presented in the ASCO session
listed below:
Sarcoma Cancer: General Poster Session Sunday, June 4, 2017,
8:00 a.m. – 11:30 a.m. CDT Abstract No.: 11058, Poster Board No.:
381 Title: Phase 2 multicenter study of the EZH2 inhibitor
tazemetostat in adults with INI1 negative epithelioid sarcoma
(NCT02601950) Location: Hall A
Sarcoma Cancer: General Poster Session Sunday, June 4, 2017,
8:00 a.m. – 11:30 a.m. CDT Abstract No.: 11057, Poster Board No.:
380 Title: Phase 2 multicenter study of the EZH2 inhibitor
tazemetostat in adults with synovial sarcoma (NCT02601950)
Location: Hall A
About the Tazemetostat Clinical Trial
ProgramTazemetostat, a first-in-class EZH2 inhibitor, is
currently being studied in ongoing phase 2 programs in non-Hodgkin
lymphoma (NHL), certain genetically defined solid tumors, including
INI1-negative and SMARCA4-negative tumors and synovial sarcoma, and
mesothelioma.
About Epizyme, Inc.Epizyme, Inc. is a
clinical-stage biopharmaceutical company committed to rewriting
cancer treatment through novel epigenetic medicines. Epizyme is
broadly developing its lead product candidate, tazemetostat, a
first-in-class EZH2 inhibitor, with studies underway in both solid
tumors and hematological malignancies as a monotherapy and
combination therapy and in relapsed and front-line disease. Using
the Company’s proprietary platform, Epizyme has pioneered the
identification and development of small molecule inhibitors of
histone methyltransferases and other chromatin modifying proteins
(CMPs), such as tazemetostat. CMPs are part of the system of gene
regulation, referred to as epigenetics, that controls gene
expression. Genetic alterations can result in changes to the
activity of CMPs, which can allow cancer cells to grow and
proliferate. By focusing on the genetic drivers of cancers,
Epizyme's science seeks to match targeted medicines with the
specific patients that need it. For more information, visit
www.epizyme.com and connect with us on Twitter at
@EpizymeRx.
Cautionary Note on Forward-Looking
StatementsAny statements in this press release about
future expectations, plans and prospects for Epizyme, Inc. and
other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict,"
"project," "target," "potential," "will," "would," "could,"
"should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: uncertainties
inherent in the initiation of future clinical studies and in the
availability and timing of data from ongoing clinical studies;
whether results from preclinical studies or earlier clinical
studies will be predictive of the results of future trials; whether
results from clinical studies will warrant meetings with regulatory
authorities or submissions for regulatory approval; expectations
for regulatory approvals to conduct trials or to market products;
whether the Company's cash resources will be sufficient to fund the
Company's foreseeable and unforeseeable operating expenses and
capital expenditure requirements; other matters that could affect
the availability or commercial potential of the Company's
therapeutic candidates; and other factors discussed in the "Risk
Factors" section of the Company's most recent Form 10-K filed with
the SEC and in the Company's other filings from time to time with
the SEC. In addition, the forward-looking statements included in
this press release represent the Company's views as of the date
hereof and should not be relied upon as representing the Company's
views as of any date subsequent to the date hereof. The Company
anticipates that subsequent events and developments will cause the
Company's views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do
so.
Contact:
Monique Allaire, THRUST IR
monique@thrustir.com
(617) 895-9511
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Epizyme (NASDAQ:EPZM)
Historical Stock Chart
From Sep 2023 to Sep 2024